Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.

Abstract: The present disclosure relates to methods and systems for generating augmented reality. The method may include capturing a first image in a viewing range of a first augmented reality device in real time via a camera of the first augmented reality device, and synchronizing the first image to a second augmented reality device, the first augmented reality device being a device for providing an augmented reality image to a first user in the first display, and the second augmented reality device being a device for providing an augmented reality image to a second user in a second display. The method further includes receiving a second image from the second augmented reality device, the second image being an image returned in real time by the second augmented reality device after augmenting the first image by the second augmented reality device.

Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.

Abstract: A delay control device, a delay control method and an electronic apparatus are provided. The delay control device includes: a trigger port, configured to receive a trigger signal; a first interface; a second interface; a control module, configured to disconnect connection between the first interface and the second interface in response to a case that the trigger port receives the trigger signal; and a timing module, configured to carry out timing for a duration; the control module is further configured to connect the first interface and the second interface in response to a case that the timing module completes timing of the duration. The delay control device can achieve a delay control function, prevent program confusion, improve efficiency and save cost.

Abstract: The present disclosure relates to methods and systems for generating augmented reality. The method may include capturing a first image in a viewing range of a first augmented reality device in real time via a camera of the first augmented reality device, and synchronizing the first image to a second augmented reality device, the first augmented reality device being a device for providing an augmented reality image to a first user in the first display, and the second augmented reality device being a device for providing an augmented reality image to a second user in a second display. The method further includes receiving a second image from the second augmented reality device, the second image being an image returned in real time by the second augmented reality device after augmenting the first image by the second augmented reality device.

Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.

Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.

Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.

Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.

Abstract: One or more processors determine a financial target for a plurality of business accounts across a plurality of product brands that are included in a business account level of an organizational hierarchy of a business organization. The organizational hierarchy includes a plurality of levels. One or more processors determine respective financial targets and quotas for a plurality of nodes included in a level of the organizational hierarchy. One or more processors determine respective financial targets for combinations of business accounts and product brands. The determination of the financial targets is based on a statistical model that is fitted at a middle level of the organizational hierarchy, and a risk-based stochastic optimization that is used to set financial targets and quotas at one or more levels of the organizational hierarchy.

Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.